Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Other Laxatives

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Attenuating effect of kaempferol on neoplastic growth in different urological malignancies.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2018

Same author

Neuroprotective Effects of Minocycline: Expanding its Use in Clinical Medicine.

The neurologist·2017

Same author

Neoplastic Growth-Restricting Effects of Fluvastatin in Systemic Malignancies.

The Journal of surgical research·2017

Same author

"Pseudo-prune belly syndrome": An under-reported phenotypic variant of prune belly syndrome.

Journal of pediatric urology·2017

Same author

Edaravone and Its Protective Effects against Disease Progression in Neurological Conditions Besides Strokes.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2017

Same author

Protective effects of wogonin against disease progression in different hepatic pathological conditions.

International immunopharmacology·2017

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

Lubiprostone: clinical applications beyond constipation.

Shailendra Kapoor

World Journal of Gastroenterology

|March 7, 2009

Summary

Lubiprostone is a valuable therapeutic agent with diverse applications beyond gastroenterology, including cystic fibrosis and uterine pathologies. Its ability to enhance chloride secretion and improve gastrointestinal visualization makes it a promising adjunctive treatment.

Area of Science:

Pharmacology
Gastroenterology
Cell Biology

Background:

Lubiprostone is increasingly utilized as an adjunctive agent in various medical fields, offering advantages over traditional treatments like polyethylene glycol.
Its therapeutic potential extends beyond gastroenterology, showing promise in managing conditions such as cystic fibrosis and uterine pathologies.

Discussion:

Lubiprostone augments chloride secretion in cystic fibrosis respiratory epithelia by activating non-cystic fibrosis transmembrane regulator (CFTR) pathways.
It improves gastrointestinal tract visualization during procedures like colonoscopy, particularly when administered before bowel preparation.
Lubiprostone stimulates colonic and gastric muscle contractions, suggesting a role as a prokinetic agent.

Key Insights:

Lubiprostone's mechanism involves activating chloride secretion via non-CFTR pathways in respiratory epithelia.

Related Experiment Videos

Last Updated: Jun 25, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

Pre-procedural administration of lubiprostone enhances bowel cleansing and gastrointestinal visualization.

The drug exhibits prokinetic effects by stimulating gastrointestinal muscle contractions.

Outlook:

Lubiprostone's ability to cause hyperpolarization in uterine muscle cells indicates potential for treating uterine pathologies.
Further research into lubiprostone's non-CFTR mediated chloride secretion could unlock new therapeutic strategies.
The multifaceted applications of lubiprostone highlight its significance in modern pharmacotherapy.